Other targeted agents tested in R/R PTCL include BCL2 inhibitors (e.g., venetoclax as single agent [NCT03552692]); JAK1/2 inhibitor ruxolitinib [NCT02974647], IDH2 inhibitors as enasidenib [NCT02273739]; monoclonal antibodies targeting CD38 (e.g., daratumumab combined with GDP[NCT04251065]); rituximab combined with lenalidomide and chidamide for R/R AITL [NCT04319601] and checkpoint inhibitors for immune modulation (e.g., pembrolizumab with pralatrexate [NCT03598998], with romidepsin [NCT03278782]). This evidence concerns the gene JAK1 and angioimmunoblastic T-cell lymphoma.